IP Library Granted Patent US 7,687,485
Granted Patent B2
US 7,687,485 · App. 10/106,381 · Granted Mar 30, 2010

Formulation for menopausal women

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,687,485
App. No.
10/106,381
Granted
Mar 30, 2010
Kind
B2
Abstract

The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from symptoms associated with menopause, as well as prophylactic effects, and methods for using same.

Claims (30)

1. A method of administering a composition to a menopausal woman, the method comprising:

administering a first fatty acid compound selected from the group consisting of a linoleic acid compound, a derivative thereof and a combination thereof in an amount of about 10 mg to about 1,000 mg; a second fatty acid compound selected from the group consisting of a linolenic acid compound, a derivative thereof and combinations thereof in an amount of about 10 mg to about 1,000 mg; a third fatty acid compound selected from the group consisting of a docosahexaenoic acid compound, an omega-3 fatty acid, an omega-2 fatty acid, a derivative thereof and a combination thereof in an amount of about 10 mg to about 1,000 mg; a calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg; a folic acid compound or derivative thereof in an amount of about 0.4 mg to about 5.0 mg; a vitamin C compound or derivative thereof in an amount of about 25 mg to about 500 mg; a vitamin E compound or derivative thereof in an amount of about 10 mg to about 500 mg; with the weight ratio of the sum of the amounts of said first and second fatty acid compounds to the amount of said third fatty acid compound being about 1:0.5 to 1.5; and with the weight ratio of the sum of the amounts of said first, second and third fatty acid compounds to the amount of said calcium compound or derivative thereof is being about 1:0.4 to 50,

and said derivatives selected from the group consisting of salts, esters, metabolites, extracts, and isolates.

2. The method of claim 1 , wherein said composition additionally contains a non-nutritional active.

3. The method of claim 2 , wherein the non-nutritional active is selected from the group consisting of hormones, steroids, fiber, estrogens, progestins, sedative-hypnotics, barbiturates, benzodiazepines, antidepressants, tranquilizers, sedatives, aminobisphosphonates, osteoporotics, herbals, herbal derivatives, phyto-chemical derivatives, antiplatelets and combinations thereof,

with said derivatives selected from the group consisting of salts, esters, metabolites, extracts, and isolates.

4. The method of claim 2 , wherein the non-nutritional active is a hormone, and with the hormone being present in said composition in an amount ranging from about 0.15 mg to about 11.25 mg.

5. The method of claim 2 , wherein the non-nutritional active is selected from the group consisting of medroxyprogesterone acetate, megestrol acetate, clonidine, norethindrone acetate, ethinyl estradiol, conjugated estrogen, natural estrogen, synthetic estrogen, estradiol, progesterone, clomiphene, clomiphene citrate, zuclomiphene, zuclomiphene citrate, enclomiphene, enclomiphene citrate, calcitonin, aspirin, alendronate, etidronate, pamidronate, clodronate, tiludronate, residronate, ibandronate and combinations thereof.

6. The method of claim 2 , wherein the non-nutritional active is an osteoporotic, and with the osteoporotic being present in said composition in an amount ranging from about 2.5 mg to about 60 mg.

7. The method of claim 1 , wherein the composition additionally contains an amino acid compound or derivative thereof,

with said derivatives selected from the group consisting of salts, esters, metabolites, extracts, and isolates.

8. The method of claim 7 , wherein the amino acid compound is selected from the group consisting of leucine, isoleucine, valine and combinations thereof.

9. A method of administering a composition to a menopausal woman, the method comprising:

administering a first fatty acid compound selected from the group consisting of a linoleic acid compound, a derivative thereof and a combination thereof in an amount of about 10 mg to about 1,000 mg; a second fatty acid compound selected from the group consisting of a linolenic acid compound, a derivative thereof and combinations thereof in an amount of about 10 mg to about 1,000 mg; a third fatty acid compound selected from the group consisting of a docosahexaenoic acid compound, an omega-3 fatty acid, an omega-2 fatty acid, a derivative thereof and a combination thereof in an amount of about 10 mg to about 1,000 mg; a calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg; a folic acid compound or derivative thereof in an amount of about 0.4 mg to about 5.0 mg; a vitamin C compound or derivative thereof in an amount of about 25 mg to about 500 mg; a vitamin E compound or derivative thereof in an amount of about 10 mg to about 500 mg; a vitamin A compound or derivative thereof in an amount of about 2,500 IU to about 6,500 IU; with the weight ratio of the sum of the amounts of said first and second fatty acid compounds to the amount of said third fatty acid compound being about 1:0.5 to 1.5; and with the weight ratio of the sum of said first, second and third fatty acid compounds to the amount of said calcium compound or derivative thereof being about 1:0.4 to 50

with said derivatives selected from the group consisting of salts, esters, metabolites, extracts, and isolates.

10. A method of administering a composition to a menopausal woman, the method comprising:

administering a first fatty acid compound selected from the group consisting of a linoleic acid compound, a derivative thereof and a combination thereof in an amount of about 10 mg to about 1,000 mg; a second fatty acid compound selected from the group consisting of a linolenic acid compound, a derivative thereof and combinations thereof in an amount of about 10 mg to about 1,000 mg; a third fatty acid compound selected from the group consisting of a docosahexaenoic acid compound, an omega-3 fatty acid, an omega-2 fatty acid, a derivative thereof and a combination thereof in an amount of about 10 mg to about 1,000 mg; a calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg; a folic acid compound or derivative thereof in an amount of about 0.4 mg to about 5.0 mg; a vitamin C compound or ester derivative thereof in an amount of about 25 mg to about 500 mg; a vitamin E compound or derivative thereof in an amount of about 10 mg to about 500 mg; a vitamin B6 compound or derivative thereof in an amount of about 10 mg to about 50 mg; a vitamin B12 compound or derivative thereof in an amount of about 25 mcg to about 75 mcg; a vitamin D compound or derivative thereof in an amount of about 200 IU to about 625 IU;

with the weight ratio of the sum of the amounts of said first and second fatty acid compounds to the amount of said third fatty acid compound being about 1:0.5 to 1.5; and with the weight ratio of the sum of the amounts of said first, second and third fatty acid compounds to the amount of said calcium compound or derivative thereof being about 1:0.4 to 50

with said derivatives selected from the group consisting of salts, esters, metabolites, extracts, and isolates.

11. A method of administering a composition to a menopausal woman, the method comprising:

administering a first fatty acid compound selected from the group consisting of a linoleic acid compound, a derivative thereof and a combination thereof in an amount of about 10 mg to about 1,000 mg; a second fatty acid compound selected from the group consisting of a linolenic acid compound, a derivative thereof and combinations thereof in an amount of about 10 mg to about 1,000 mg; a third fatty acid compound selected from the group consisting of a docosahexaenoic acid compound, an omega-3 fatty acid, an omega-2 fatty acid, a derivative thereof and a combination thereof in an amount of about 10 mg to about 1,000 mg; a calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg; a folic acid compound or derivative thereof in an amount of about 0.4 mg to about 5.0 mg; a vitamin C compound or derivative thereof in an amount of about 25 mg to about 500 mg; a vitamin E compound or derivative thereof in an amount of about 10 mg to about 500 mg; and with the weight ratio of the sum of the amounts of said first, second and third fatty acid compounds to the amount of said calcium compound or derivative thereof being about 1:0.4 to 50

with said derivatives selected from the group consisting of salts, esters, metabolites, extracts, and isolates.

12. The method of claim 11 , wherein said composition additionally contains a non-nutritional active.

13. The method of claim 12 , wherein the non-nutritional active is selected from the group consisting of hormones, steroids, fiber, estrogens, progestins, sedative-hypnotics, barbiturates, benzodiazepines, antidepressants, tranquilizers, sedatives, aminobisphosphonates, osteoporotics, herbals, herbal derivatives, phyto-chemical derivatives, antiplatelets and combinations thereof.

14. The method of claim 12 , wherein the non-nutritional active is a hormone, and with the hormone being present in said composition in an amount ranging from about 0.15 mg to about 11.25 mg.

15. The method of claim 12 , wherein the non-nutritional active is selected from the group consisting of medroxyprogesterone acetate, megestrol acetate, clonidine, norethindrone acetate, ethinyl estradiol, conjugated estrogen, natural estrogen, synthetic estrogen, estradiol, progesterone, clomiphene, clomiphene citrate, zuclomiphene, zuclomiphene citrate, enclomiphene, enclomiphene citrate, calcitonin, aspirin, alendronate, etidronate, pamidronate, clodronate, tiludronate, residronate, ibandronate and combinations thereof.

16. The method of claim 12 , wherein the non-nutritional active is an osteoporotic, and with the osteoporotic being present in said composition in an amount ranging from about 2.5 mg to about 60 mg.

17. The method of claim 11 , wherein the composition additionally contains an amino acid compound or derivative thereof

with said derivatives selected from the group consisting of salts, esters, metabolites, extracts, and isolates.

18. The method of claim 17 , wherein the amino acid compound is selected from the group consisting of leucine, isoleucine, valine and combinations thereof.

Assignments (15)
MERGER AND CHANGE OF NAME Recorded Jan 3, 2018
From: AMAG PHARMACEUTICALS IP, LTD.; AMAG PHARMA USA, INC.
To: AMAG PHARMA USA, INC.
Reel/Frame 044523/0160 →
CHANGE OF NAME Recorded Dec 27, 2017
From: LUMARA HEALTH IP LTD.
To: AMAG PHARMACEUTICALS IP, LTD.
Reel/Frame 044961/0232 →
RELEASE OF SECURITY INTEREST Recorded May 15, 2017
From: JEFFERIES FINANCE LLC
To: LUMARA HEALTH IP LTD.
Reel/Frame 042461/0626 →
RELEASE OF SECURITY INTEREST Recorded Oct 9, 2015
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: LUMARA HEALTH IP LTD.
Reel/Frame 036763/0475 →
RELEASE OF SECURITY INTEREST Recorded Oct 1, 2015
From: WILLMINGTON TRUST, NATIONAL ASSOCIATION
To: LUMARA HEALTH IP LTD
Reel/Frame 036704/0822 →
SECURITY INTEREST Recorded Sep 25, 2015
From: LUMARA HEALTH IP LTD.
To: JEFFERIES FINANCE LLC
Reel/Frame 036653/0138 →
SECURITY INTEREST Recorded Nov 12, 2014
From: LUMARA HEALTH IP LTD
To: JEFFERIES FINANCE LLC
Reel/Frame 034156/0243 →
RELEASE OF SECURITY INTERESTS IN INTELLECTUAL PROPERTY Recorded Oct 20, 2014
From: LAW DEBENTURE TRUST COMPANY OF NEW YORK
To: K-V PHARMACEUTICAL COMPANY
Reel/Frame 034018/0040 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2014
From: LEVINSON, R. SAUL; HERMELIN, MARC S.; KIRSCHNER, MITCHELL I.
To: KV PHARMACEUTICAL COMPANY
Reel/Frame 033269/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2014
From: K-V PHARMACEUTICAL COMPANY
To: DRUGTECH CORPORATION
Reel/Frame 033269/0301 →
CHANGE OF NAME Recorded Jul 9, 2014
From: DRUGTECH CORPORATION
To: LUMARA HEALTH IP LTD.
Reel/Frame 033282/0265 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: DRUGTECH CORPORATION
To: LAW DEBENTURE TRUST COMPANY OF NEW YORK, AS AGENT
Reel/Frame 031226/0883 →
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE I, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025981/0934 →
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025980/0024 →
SECURITY AGREEMENT Recorded Mar 18, 2011
From: DRUGTECH CORPORATION
To: WILMINGTON TRUST FSB (AS COLLATERAL AGENT)
Reel/Frame 025981/0068 →